Barr Pharmaceuticals Inc.: PharmaVitae Profile

This analysis examines the historical and forecast performance for Barr in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Report Highlights

[Studien Infos ausblenden]

Table 1: Barr - PharmaVitae forecasts at a glance 7
Table 2: Barr key product developments, Q1-Q3 2008 19
Table 3: Barr product deals and alliances, Q1-Q3 2008 20
Table 4: Barr technology deals and alliances, Q1-Q3 2008 21
Table 5: Barr M&A activity, Q1-Q3 2008 21
Table 6: Barr company announcements, Q1-Q3 2008 22
Table 7: Barr future product milestones, 2008-10 22
Table 8: Barr product portfolio overview ($m), 2001-07 30
Table 9: Barr product portfolio overview ($m), 2007-13 34
Table 10: Barr product portfolio overview ($m), 2001-07 40
Table 11: Barr product portfolio overview ($m), 2007-13 42
Table 12: Barr portfolio overview by geographic region ($m), 2001-07 48
Table 13: Barr portfolio overview by geographic region ($m), 2007-13 49
Table 14: Barr launch portfolio overview ($m), 2007-13 53
Table 15: Barr core portfolio overview ($m), 2007-13 55
Table 16: Barr expiry portfolio overview ($m), 2007-13 57
Table 17: Barr portfolio overview by molecule type ($m), 2001-07 60
Table 18: Barr product portfolio overview by molecule type ($m), 2007-13 61
Table 19: Barr product portfolio overview by source ($m), 2001-07 66
Table 20: Barr product portfolio overview by source ($m), 2007-13 67
Table 21: Total Barr sales by business unit ($m), 2001-07 72
Table 22: Barr profit and loss account ($m), 2001-07 74
Table 23: Barr balance sheet ($m), 2001-07 76
Table 24: Barr operating revenue/cost analysis ($m), 2001-07 80
Table 25: Barr operating cost ratio analysis (% of total revenues), 2001-07 82
Table 26: Barr operating cost ratio analysis (% of total revenues), 2007-13 84
Table 27: Barr operating revenue/cost analysis ($m), 2007-13 86
Table 28: Barr capital employed ($m), 2001-07 89
Table 29: Barr EBIT return on capital employed ($m), 2001-07 91
Table 30: Barr EBIT pre-tax return/Capital employed driver analysis (%), 2001-07 92
Table 31: Seasonale: overview 96
Table 32: Seasonale: sales forecast ($m), 2007-13 97
Table 33: Seasonique: sales forecast ($m), 2007-13 97
Table 34: Ocella; generic Yasmin: overview 99
Table 35: gen. Yasmin: sales forecast ($m), 2007-13 99
Table 36: generic Adderall XR: overview 101
Table 37: gen. Adderall XR: sales forecast ($m), 2007-13 101
Table 38: Exchange rates, 2007 104
Figure 1: Barr prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13 5
Figure 2: Barr's financial performance ($m), 2001-13xx 6
Figure 3: Illustrative branded and generic product lifecycles 8
Figure 4: Growth strategies employed by Barr 10
Figure 5: Barr prescription pharmaceutical sales ($m), 2001-13 12
Figure 6: Barr SWOT analysis 15
Figure 7: Barr's M&A history, 2001-06 25
Figure 8: Barr prescription pharmaceutical performance, sales ($m) and growth rate (%), 2001-13 27
Figure 9: Barr key sales growth driver & resistors ($m), 2001-07 31
Figure 10: Barr prescription pharmaceutical sales ($m), 2001-07 32
Figure 11: Barr key sales growth drivers & resistors ($m), 2007-13 36
Figure 12: Barr prescription pharmaceutical sales by therapy area ($m), 2001-13 39
Figure 13: Barr prescription pharma sales by therapy area (% of total), 2001-13 46
Figure 14: Barr prescription pharmaceutical sales by geographic region ($m), 2001-13 47
Figure 15: Barr growth drivers and resistors by geographic region ($m), 2001-07 48
Figure 16: Barr drivers and resistors by geographic region ($m), 2007-13 50
Figure 17: Barr prescription pharmaceutical sales by geographic region (% of total), 2001-13 51
Figure 18: Barr launch/core/expiry configuration ($m), 2007-13 58
Figure 19: Barr prescription pharmaceutical sales by molecule type ($m), 2001-13 59
Figure 20: Barr growth drivers and resistors by molecule type ($m), 2007-13 64
Figure 21: Barr prescription pharmaceutical sales by source ($m), 2001-13 65
Figure 22: Barr growth drivers and resistors by source ($m), 2001-07 66
Figure 23: Barr growth drivers and resistors by source ($m), 2007-13 69
Figure 24: Barr operating revenue/cost analysis ($m), 2001-13 79
Figure 25: Barr operating cost ratio analysis (% of total revenues), 2001-13 85
Figure 26: Barr return on capital employed, EBIT margin and capital turnover, 2001-07 88
Figure 27: Return on capital employed formula 92
[Tabellenverzeichnis ausblenden]